Bio-Technology General (Israel) Ltd. (BTG) was founded in October 1980 by Professor Haim Aviv and colleagues from the Weizmann Institute of Science in order to take advantage of what was then the new science of genetic engineering. The company was established as a wholly-owned subsidiary of Bio-Technology General Corp. in New York, with a primary mission of developing and manufacturing human health care products, primarily those derived from genetic engineering and biotechnology processes. BTG, one of the first such companies in Israel as well as in the world, was initially located in the Kiryat Weizmann Science Park adjacent to the Weizmann Institute.
In addition to its pharmaceutical pursuits, BTG was also involved at the outset in agricultural projects such as animal growth hormones, foot and mouth disease vaccine, Azopirillum, etc., but by the mid 1980’s terminated its agricultural pursuits to focus entirely on human health care products. During this period, BTG Corp. went public on the NASDAQ; BTG Corp. later changed its name to Savient Pharmaceuticals Inc.
BTG obtained initial product regulatory approvals in the late 1980’s and throughout the 1990’s. In 1999, the company acquired a site in Beer Tuvia, built a new facility on the site and during the period 2003-2007 moved to the Beer Tuvia facility and closed the Kiryat Weizmann plant. In 2005, BTG was sold by Savient to Ferring Pharmaceuticals, a privately-held, multinational company headquartered in Switzerland.
Today, more than 300 BTG employees at the Beer Tuvia site are still engaged in the development, manufacture and marketing of health care products derived from genetic engineering and biotechnology processes, and the company is a Center for Excellence in Biotechnology for Ferring’s Development and Manufacturing networks.
BTG founded, begins work on Azospirillum, Trichoderma, Foot & Mouth Disease, Bovine Growth Hormone
Work begins on NaHA, Human Growth Hormone
Agreement with American Cyanamid on bGH development
Agreement with Pharmacia on NaHA development
Move to building 17, Kiryat Weizmann
Human Growth hormone approved by Israel Ministry of Health
Human Growth hormone approved by EMEA in first approval by new centralized procedure
Agreement with Ferring on hGH November 9, 1992
Recombinant Human Growth hormone approval in Japan for short stature
BIOLON approved in Europe (CE mark)
Human Growth hormone approved by US FDA
Recombinant insulin licensed to Bioton and to Diosynth
Agreement with JCR on hGH October 10, 1998
Beer Tuvia site acquired
Bio-Hep-B (company’s Hepatitis B vaccine) approval in Israel
Arthrease (EUFLEXXA) approved in Europe (CE mark) and Israel
Move to Beer Tuvia
EUFLEXXA approved by US FDA
BTG acquired by Ferring
Pegloticase approved by US FDA
REKOVELLE was first approved in EU
REKOVELLE was approved in Australia, Brazil, Israel, Switzerland, Canada and Mexico.
Agreement on BIOLON with Altacor/Amring
REKOVELLE approved in Costa Rica, Dominican Republic, Hong Kong, Mexico, Singapore
REKOVELLE approved in Bolivia, Chile, El Salvador, Honduras, Jamaica, Kazakhstan, Korea, Serbia, Trinidad and Tobago